251 related articles for article (PubMed ID: 30003393)
1. The clinical relevance of serum vascular endothelial growth factor (VEGF) in correlation to circulating tumor cells and other serum biomarkers in patients with metastatic breast cancer.
Banys-Paluchowski M; Witzel I; Riethdorf S; Pantel K; Rack B; Janni W; Fasching PA; Aktas B; Kasimir-Bauer S; Hartkopf A; Solomayer EF; Fehm T; Müller V
Breast Cancer Res Treat; 2018 Nov; 172(1):93-104. PubMed ID: 30003393
[TBL] [Abstract][Full Text] [Related]
2. Elevated serum RAS p21 is an independent prognostic factor in metastatic breast cancer.
Banys-Paluchowski M; Fehm T; Janni W; Aktas B; Fasching PA; Kasimir-Bauer S; Milde-Langosch K; Pantel K; Rack B; Riethdorf S; Solomayer EF; Witzel I; Müller V
BMC Cancer; 2018 May; 18(1):541. PubMed ID: 29739347
[TBL] [Abstract][Full Text] [Related]
3. The prognostic relevance of urokinase-type plasminogen activator (uPA) in the blood of patients with metastatic breast cancer.
Banys-Paluchowski M; Witzel I; Aktas B; Fasching PA; Hartkopf A; Janni W; Kasimir-Bauer S; Pantel K; Schön G; Rack B; Riethdorf S; Solomayer EF; Fehm T; Müller V
Sci Rep; 2019 Feb; 9(1):2318. PubMed ID: 30783124
[TBL] [Abstract][Full Text] [Related]
4. Clinical Relevance of Serum HER2 and Circulating Tumor Cell Detection in Metastatic Breast Cancer Patients.
Banys-Paluchowski M; Witzel I; Riethdorf S; Rack B; Janni W; Fasching PA; Solomayer EF; Aktas B; Kasimir-Bauer S; Pantel K; Fehm T; Müller V
Anticancer Res; 2017 Jun; 37(6):3117-3128. PubMed ID: 28551653
[TBL] [Abstract][Full Text] [Related]
5. Prospective evaluation of serum tissue inhibitor of metalloproteinase 1 and carbonic anhydrase IX in correlation to circulating tumor cells in patients with metastatic breast cancer.
Müller V; Riethdorf S; Rack B; Janni W; Fasching PA; Solomayer E; Aktas B; Kasimir-Bauer S; Zeitz J; Pantel K; Fehm T;
Breast Cancer Res; 2011 Jul; 13(4):R71. PubMed ID: 21745383
[TBL] [Abstract][Full Text] [Related]
6. Prognostic impact of circulating tumor cell apoptosis and clusters in serial blood samples from patients with metastatic breast cancer in a prospective observational cohort.
Jansson S; Bendahl PO; Larsson AM; Aaltonen KE; Rydén L
BMC Cancer; 2016 Jul; 16():433. PubMed ID: 27390845
[TBL] [Abstract][Full Text] [Related]
7. Serum interleukin 6, plasma VEGF, serum VEGF, and VEGF platelet load in breast cancer patients.
Benoy I; Salgado R; Colpaert C; Weytjens R; Vermeulen PB; Dirix LY
Clin Breast Cancer; 2002 Jan; 2(4):311-5. PubMed ID: 11899364
[TBL] [Abstract][Full Text] [Related]
8. Longitudinal enumeration and cluster evaluation of circulating tumor cells improve prognostication for patients with newly diagnosed metastatic breast cancer in a prospective observational trial.
Larsson AM; Jansson S; Bendahl PO; Levin Tykjaer Jörgensen C; Loman N; Graffman C; Lundgren L; Aaltonen K; Rydén L
Breast Cancer Res; 2018 Jun; 20(1):48. PubMed ID: 29884204
[TBL] [Abstract][Full Text] [Related]
9. Prognostic impact of circulating tumor cells assessed with the CellSearch System™ and AdnaTest Breast™ in metastatic breast cancer patients: the DETECT study.
Müller V; Riethdorf S; Rack B; Janni W; Fasching PA; Solomayer E; Aktas B; Kasimir-Bauer S; Pantel K; Fehm T;
Breast Cancer Res; 2012 Aug; 14(4):R118. PubMed ID: 22894854
[TBL] [Abstract][Full Text] [Related]
10. Prognostic values of cancer associated macrophage-like cells (CAML) enumeration in metastatic breast cancer.
Mu Z; Wang C; Ye Z; Rossi G; Sun C; Li L; Zhu Z; Yang H; Cristofanilli M
Breast Cancer Res Treat; 2017 Oct; 165(3):733-741. PubMed ID: 28687903
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of serum epidermal growth factor receptor (EGFR) in correlation to circulating tumor cells in patients with metastatic breast cancer.
Banys-Paluchowski M; Witzel I; Riethdorf S; Rack B; Janni W; Fasching PA; Solomayer EF; Aktas B; Kasimir-Bauer S; Pantel K; Fehm T; Müller V
Sci Rep; 2017 Dec; 7(1):17307. PubMed ID: 29229933
[TBL] [Abstract][Full Text] [Related]
12. Prospective validation of the prognostic value of elevated serum vascular endothelial growth factor in patients with nasopharyngeal carcinoma: more distant metastases and shorter overall survival after treatment.
Lv X; Xiang YQ; Cao SM; Qian CN; Li NW; Guo L; Mai HQ; Chen QY; Huang PY; Luo D; Cao KJ; Hong MH; Guo X
Head Neck; 2011 Jun; 33(6):780-5. PubMed ID: 20967862
[TBL] [Abstract][Full Text] [Related]
13. Correlation of serum VEGF levels with clinical stage, therapy efficacy, tumor metastasis and patient survival in ovarian cancer.
Li L; Wang L; Zhang W; Tang B; Zhang J; Song H; Yao D; Tang Y; Chen X; Yang Z; Wang G; Li X; Zhao J; Ding H; Reed E; Li QQ
Anticancer Res; 2004; 24(3b):1973-9. PubMed ID: 15274387
[TBL] [Abstract][Full Text] [Related]
14. [Relationship between serum VEGF level and VEGF, COX-2 and MVD expression in breast cancer tissues].
Li EX; Wu YY; Shi F; Wu Y; Guo JJ; Dong DF
Zhonghua Zhong Liu Za Zhi; 2007 Jul; 29(7):522-5. PubMed ID: 18069633
[TBL] [Abstract][Full Text] [Related]
15. Detection of circulating tumor cells using manually performed immunocytochemistry (MICC) does not correlate with outcome in patients with early breast cancer - Results of the German SUCCESS-A- trial.
Jueckstock J; Rack B; Friedl TW; Scholz C; Steidl J; Trapp E; Tesch H; Forstbauer H; Lorenz R; Rezai M; Häberle L; Alunni-Fabbroni M; Schneeweiss A; Beckmann MW; Lichtenegger W; Fasching PA; Pantel K; Janni W;
BMC Cancer; 2016 Jul; 16():401. PubMed ID: 27387743
[TBL] [Abstract][Full Text] [Related]
16. Circulating tumor cells as a prognostic marker for efficacy in the randomized phase III JO21095 trial in Japanese patients with HER2-negative metastatic breast cancer.
Iwata H; Masuda N; Yamamoto D; Sagara Y; Sato N; Yamamoto Y; Saito M; Fujita T; Oura S; Watanabe J; Tsukabe M; Horiguchi K; Hattori S; Matsuura Y; Kuroi K
Breast Cancer Res Treat; 2017 Apr; 162(3):501-510. PubMed ID: 28181129
[TBL] [Abstract][Full Text] [Related]
17. Circulating tumor cells and serum levels of MMP-2, MMP-9 and VEGF as markers of the metastatic process in patients with high risk of metastatic progression.
Skerenova M; Mikulova V; Capoun O; Zima T; Tesarova P
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2017 Sep; 161(3):272-280. PubMed ID: 28529342
[TBL] [Abstract][Full Text] [Related]
18. The impact of HER2 phenotype of circulating tumor cells in metastatic breast cancer: a retrospective study in 107 patients.
Wallwiener M; Hartkopf AD; Riethdorf S; Nees J; Sprick MR; Schönfisch B; Taran FA; Heil J; Sohn C; Pantel K; Trumpp A; Schneeweiss A
BMC Cancer; 2015 May; 15():403. PubMed ID: 25972110
[TBL] [Abstract][Full Text] [Related]
19. Soluble Vascular Endothelial Growth Factor (sVEGF) and the Risk of Venous Thromboembolism in Patients with Cancer: Results from the Vienna Cancer and Thrombosis Study (CATS).
Posch F; Thaler J; Zlabinger GJ; Königsbrügge O; Koder S; Zielinski C; Pabinger I; Ay C
Clin Cancer Res; 2016 Jan; 22(1):200-6. PubMed ID: 26302981
[TBL] [Abstract][Full Text] [Related]
20. Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer.
Cristofanilli M; Hayes DF; Budd GT; Ellis MJ; Stopeck A; Reuben JM; Doyle GV; Matera J; Allard WJ; Miller MC; Fritsche HA; Hortobagyi GN; Terstappen LW
J Clin Oncol; 2005 Mar; 23(7):1420-30. PubMed ID: 15735118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
